Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue rose 48% and royalty revenue 50%; HALO beat expectations and raised 2026 revenue and EBITDA guidance. Shares gained 27.2% through August 28 and remain above the 21-day average, supported by multiple product launches and licensing agreements.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional Margins ⢠Heavy Leverage ⢠Adequate Liquidity HALO delivers exceptional profitability and cash flow, but its extreme leverage, intangible-heavy assets, and high price-to-book warrant caution despite moderating valuation.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Strong late momentum ⢠Overbought conditions Support Level: $109â$110 (stronger: $106â$107) Resistance Level: $112.45 HALO rose about 6% over the last month to a period high of $112.45, with bullish momentum favoring a breakout above resistance but an overbought RSI signaling pullback risk toward $109â$110 support.
Sentiment & News
Key News Insights: ⢠Royalty acceleration ⢠Raised guidance ⢠Upsized financing Halozyme's accelerating royalty growth, raised guidance, and growing institutional support strengthen its outlook, though the $1.3B convertible offering and insider selling warrant monitoring.
AI Summary
HALO has evolved into a high-margin, cash-generative royalty infrastructure business, but at new highs investors should require continued 50% royalty growth and successful conversion of new platform deals while monitoring rising convert debt and partner-therapy dependence.
Description
Halozyme Therapeutics is a multinational biopharma technology company that develops and licenses a proprietary recombinant human hyaluronidase enzyme (rHuPH20) and the ENHANZE delivery technology to enable subcutaneous administration of biologics, small molecules and fluids. Its marketed offering includes Hylenex recombinant, and the company supplies or collaborates on subcutaneous formulations and pipeline programs across oncology and immunology with a range of large pharmaceutical partners. Halozyme was founded in 1998 and is headquartered in San Diego, with operations in multiple countries including Switzerland, Ireland, Belgium and Japan.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 28 | Sep 4 | HALO | Halozyme Therapeutics, Inc. | Q2 revenue rose 48% and royalty revenue 50%; HALO beat expectations and raised 2026 revenue and EBITDA guidance. Shares gained 27.2% through August 28 and remain above the 21-day average, supported by multiple product launches and licensing agreements. | Closed | +4.6% |
| Aug 11 | Aug 18 | HALO | Halozyme Therapeutics, Inc. | Strong biotech/pharma earnings catalyst: Q2 2026 revenue rose 48% YoY to $481M, royalty revenue rose 50%, management raised full-year revenue, adjusted EBITDA, and non-GAAP EPS guidance, added an Incyte ENHANZE collaboration, and stock broke out sharply on 2026-08-07. | Closed | +2.2% |